[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 89
Citations 0
Letters
January 25, 2012

BRCA1 and BRCA2 Mutations in Ovarian Cancer—Reply

Author Affiliations

Author Affiliations: Departments of Pathology (Drs Zhang and Yang) (wzhang@mdanderson.org) and Gynecologic Oncology and Reproductive Medicine (Dr Sood), University of Texas MD Anderson Cancer Center, Houston.

JAMA. 2012;307(4):359-361. doi:10.1001/jama.2012.10

In Reply: Drs Buerkle and Tempfer asked whether differences in progression-free survival and primary chemotherapy response between BRCA1 - and BRCA2 -mutated cases could be the result of unbalanced distribution of disease stages and extent of cytoreduction. The distribution of cytoreduction outcomes between BRCA1 - and BRCA2 -mutated cases was similar (P = .94; Table 1 in the article). Although there was an apparent difference in the proportion of stage IV cases between BRCA1- and BRCA2- mutated cases, it was not significant (P = .28).

First Page Preview View Large
First page PDF preview
First page PDF preview
×